Literature DB >> 12814898

Subnormal alpha-2-adrenoceptor-mediated sedation during 6 months of sobriety in male type 1 alcohol-dependent subjects.

Ulf Berggren1, Kristina Berglund, Matts Eriksson, Claudia Fahlke, Olof Zachrisson, Jan Balldin.   

Abstract

AIMS: In the present study, alpha(2)-adrenoceptor function was investigated over 6 months of sobriety in eight male alcohol-dependent subjects.
METHODS: Subjects were investigated with repeated clonidine (CLON, 2 micro g/kg body weight intravenously) challenge tests at days 1 and 7, and months 2 and 6 after the end of a period of heavy alcohol intake. CLON-induced sedation was rated at challenge tests. Mental well-being was self-reported before all challenge tests. Three challenge tests were performed at 1-week intervals in six male healthy controls.
RESULTS: Sedation was significantly lower after CLON at all time-points for the challenge tests in alcohol-dependent subjects compared with mean values for three challenge tests in controls. Three dimensions of mental well-being were negatively correlated with scores of CLON-induced sedation at month 6.
CONCLUSIONS: alpha(2)-Adrenoceptor function is subnormal, as assessed by CLON-induced sedation, for at least 6 months after termination of alcohol intake. Whether this subnormal receptor function is pre-existing and possibly genetically determined or is a consequence of long-term alcohol intake must be further investigated, as should this receptor status in alcohol-dependent subjects with longer time-periods of sobriety.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12814898     DOI: 10.1093/alcalc/agg086

Source DB:  PubMed          Journal:  Alcohol Alcohol        ISSN: 0735-0414            Impact factor:   2.826


  1 in total

1.  Dexmedetomidine impairs success of patient-controlled sedation in alcoholics during ERCP: a randomized, double-blind, placebo-controlled study.

Authors:  Max Mazanikov; Marianne Udd; Leena Kylänpää; Harri Mustonen; Outi Lindström; Jorma Halttunen; Reino Pöyhiä
Journal:  Surg Endosc       Date:  2013-01-26       Impact factor: 4.584

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.